Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patients With Structural Heart Disease

Recruiting now · Phase 1

Conditions studied: Atrial Fibrillation

In brief

This is a prospective comparative study, conducted at Cardiology Department, Aswan University Hospital on AF patients with structural heart disease. Eplerenone 25 mg daily will be given and searching for AF recurrence among study population.

Key facts

Study ID

NCT06556732

Run by

Assiut University

People needed

100

Starts

2024-08-10

Expected to finish

2024-08-31

Last updated by the study team

2024-08-16

Who can join

Age: 20 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Patients with non-valvular AF who underwent cardioversion to sinus rhythm either medical, electrical or even spontaneously

You may not qualify if…

• Patients with rheumatic heart disease.
• Thyroid dysfunction.
• Wolf-Parkinson-White (WPW) syndrome.
• Renal impairment.
• Hyperkalemia.
• Acute coronary syndrome.
• Pregnancy.
• Left ventricular (LV) dysfunction with ejection fraction (EF) less than 40%.
• On current use of eplerenone.

Where it is running

• Assiut University Heart Hospital — Asyut, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.